Press Releases

Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™   May 18, 2017 Eastern Standard Time ROCKVILLE, Md. & SAN FRANCISCO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held,

ROCKVILLE, Md., May 16, 2016 /PRNewswire/ -- At the North Bethesda Marriott, Maryland's leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in the

November 08, 2016 07:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced they are now accepting applications for their Cancer Discovery

January 05, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board. “We could not

ITI announced the issuance of a new United States Patent which extends ITI’s intellectual property portfolio covering their proprietary vectors, including ITI’s out-licensed investigational DNA vaccines. Specifically, U.S. Patent No. 9,499,589

ASTELLAS Announces FDA Fast Track Designation for ASP0892 DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions Due to Peanut Allergy NEWS PROVIDED BY Astellas Pharma Inc. Dec 20, 2016, 08:00

February 02, 2017 06:45 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the finalists for their Cancer Discovery Incubator Award: Alcamena

January 05, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board. “We could not

TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas") and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., "Immunomic Therapeutics") today announced that the

December 14, 2016 07:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces that C. Eric Winzer, M.B.A., currently serving Immunomic as Chief

Announces Issuance of Patent Related to LAMP-Vax™ Technology November 22, 2016 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the

Johns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration On Tues., Nov. 10, Johns Hopkins University and Immunomic Therapeutics, Inc. celebrated the success of the LAMP-Vax platform. The technology